pre-gestational diabetes: a public health growth industry evan klass, md, facp associate dean,...

28
Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Upload: nicholas-norman

Post on 17-Jan-2018

216 views

Category:

Documents


0 download

DESCRIPTION

Definitions Gestational Diabetes (GDM)-Diabetes not detected before pregnancy but discovered during pregnancy. Nearly all (but not all)cases are Type 2 Diabetes Pre-gestational Diabetes (PGDM)- Diabetes diagnosed before conception. Includes women with Type 1 and Type 2 Diabetes

TRANSCRIPT

Page 1: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Pre-Gestational Diabetes:A Public Health Growth Industry

Evan Klass, MD, FACPAssociate Dean, Statewide Initiatives

Director, Project ECHO-Nevada

Page 2: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Goals for today

• 1) Recognize the importance of pre-gestational Diabetes and its magnitude

• 2) Understand the difference between pre- gestational and gestational Diabetes and the implications of each

• 3) Consider opportunities for intervention to reduce the health impact of pre-gestational Diabetes

• I have no financial conflicts to report

Page 3: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Definitions

• Gestational Diabetes (GDM)-Diabetes not detected before pregnancy but discovered during pregnancy. Nearly all (but not all)cases are Type 2 Diabetes

• Pre-gestational Diabetes (PGDM)- Diabetes diagnosed before conception. Includes women with Type 1 and Type 2 Diabetes

Page 4: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

How big a problem is this?

• Women of child bearing age= 63M• Prevalence of know Type 1 DM= 1%

– 630K women• Prevalence of known Type 2 DM= 2.9%

– 1.8M women• Prevalence of unknown Type 2 DM= 0.5%

– 314K womenSO: 2.7 million women with preconception Diabetes!

Page 5: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

http://main.diabetes.org/site/R?i=CcKLVT2ni5UsLHCbVf1bmw

Rate of new cases of type 1 and type 2 diabetes among people younger than 20 years, by age and race/ethnicity, 2008–2009

Source: SEARCH for Diabetes in Youth Study. NHW=non-Hispanic whites; NHB=non-Hispanic blacks; H=Hispanics; API=Asians/Pacific Islanders; AIAN=American Indians/Alaska Natives.*The American Indian/Alaska Native (AI/AN) youth who participated in the SEARCH study are not representative of all AI/AN youth in the United States. Thus, these rates cannot be generalized to all AI/AN youth nationwide.

<10 years 10–19 years

Page 6: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Prevalence of Type 2 Diabetes by Age

Page 7: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Fig. 2. Age-adjusted incidence of pre-gestational diabetes and gestational diabetes over time.

Alex Fong, Allison Serra, Tiffany Herrero, Deyu Pan, Dotun Ogunyemi

Pre-gestational versus gestational diabetes: A population based study on clinical and demographic differences ☆

Journal of Diabetes and its Complications, Volume 28, Issue 1, 2014, 29–34

http://dx.doi.org/10.1016/j.jdiacomp.2013.08.009

Page 8: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Fig. 4. Age-adjusted prevalence of PGDM and GDM by race/ethnicity.

Alex Fong, Allison Serra, Tiffany Herrero, Deyu Pan, Dotun Ogunyemi

Pre-gestational versus gestational diabetes: A population based study on clinical and demographic differences ☆

Journal of Diabetes and its Complications, Volume 28, Issue 1, 2014, 29–34

http://dx.doi.org/10.1016/j.jdiacomp.2013.08.009

Page 9: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Risk of birth defects associated with pregestational diabetes

• Reviewed all pregnancies in Emilia-Romagna region between 1997-2010

• Malformations in 62/2269 diabetic pregnancies vs. 162/10,648 non-diabetic (1:5 cases/controls)– Prevalence ratio of 1.79 (controls were age-matched)– Prevalence ratio was 0.94 for probable type 1 patients and 4.89 for

probable type 2 patients

Vinceti M et al. Risk of birth defects associated with maternal pregestational diabetes. Eur J Epidemiol 29:411-18

Fig. 4 Age-adjusted prevalence of PGDM and GDM by race/ethnicity.

Alex Fong , Allison Serra , Tiffany Herrero , Deyu Pan , Dotun Ogunyemi

Pre-gestational versus gestational diabetes: A population based study on clinical and demographic differences

Journal of Diabetes and its Complications, Volume 28, Issue 1, 2014, 29 - 34

http://dx.doi.org/10.1016/j.jdiacomp.2013.08.009

Fig. 2 Age-adjusted incidence of pre-gestational diabetes and gestational diabetes over time.

Alex Fong , Allison Serra , Tiffany Herrero , Deyu Pan , Dotun Ogunyemi

Pre-gestational versus gestational diabetes: A population based study on clinical and demographic differences

Journal of Diabetes and its Complications, Volume 28, Issue 1, 2014, 29 - 34

http://dx.doi.org/10.1016/j.jdiacomp.2013.08.009

Fig. 3 Prevalence of pre-gestational diabetes compared to gestational diabetes in pregnancy by age range.

Alex Fong , Allison Serra , Tiffany Herrero , Deyu Pan , Dotun Ogunyemi

Pre-gestational versus gestational diabetes: A population based study on clinical and demographic differences

Journal of Diabetes and its Complications, Volume 28, Issue 1, 2014, 29 - 34

http://dx.doi.org/10.1016/j.jdiacomp.2013.08.009

Page 10: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

A: Risk of a major or minor congenital anomaly according to the number of SDs of GHb above normal, measured periconceptionally.

Andrea Guerin et al. Dia Care 2007;30:1920-1925

©2007 by American Diabetes Association

Page 11: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Figure 1. Hyperglycemia-induced oxidative stressSustained generation of reactive oxygen species (ROS) by maternal diabetes-related hyperglycemia activates p66shc by phosphorylation (+P), which further causes mitochondrial dysfunction, aggravating ROS generatio...

Peixin Yang, E. Albert Reece, Fang Wang, Rinat Gabbay-Benziv

Decoding the oxidative stress hypothesis in diabetic embryopathy through proapoptotic kinase signaling

American Journal of Obstetrics and Gynecology, Volume 212, Issue 5, 2015, 569–579

http://dx.doi.org/10.1016/j.ajog.2014.11.036

Page 12: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Figure 2. Oxidative stress-induced proapoptotic PKC signalingMaternal diabetes-induced oxidative stress activates PKC α, βII, δ, while it inhibits PKCε, ξ. Activated PKCα induces lipid peroxidation, which in turn aggravates oxidative stress, and induces apopto...

Peixin Yang, E. Albert Reece, Fang Wang, Rinat Gabbay-Benziv

Decoding the oxidative stress hypothesis in diabetic embryopathy through proapoptotic kinase signaling

American Journal of Obstetrics and Gynecology, Volume 212, Issue 5, 2015, 569–579

http://dx.doi.org/10.1016/j.ajog.2014.11.036

Figure 2. Oxidative stress-induced proapoptotic PKC signalingMaternal diabetes-induced oxidative stress activates PKC α, βII, δ, while it inhibits PKCε, ξ. Activated PKCα induces lipid peroxidation, which in turn aggravates oxidative stress, and induces apopto...

Peixin Yang, E. Albert Reece, Fang Wang, Rinat Gabbay-Benziv

Decoding the oxidative stress hypothesis in diabetic embryopathy through proapoptotic kinase signaling

American Journal of Obstetrics and Gynecology, Volume 212, Issue 5, 2015, 569 –579

http://dx.doi.org/10.1016/j.ajog.2014.11.036

Figure 2. Oxidative stress-induced proapoptotic PKC signalingMaternal diabetes-induced oxidative stress activates PKC α, βII, δ, while it inhibits PKCε, ξ. Activated PKCα induces lipid peroxidation, which in turn aggravates oxidative stress, and induces apopto...

Peixin Yang, E. Albert Reece, Fang Wang, Rinat Gabbay-Benziv

Decoding the oxidative stress hypothesis in diabetic embryopathy through proapoptotic kinase signaling

American Journal of Obstetrics and Gynecology, Volume 212, Issue 5, 2015, 569–579

http://dx.doi.org/10.1016/j.ajog.2014.11.036

Figure 2. Oxidative stress-induced proapoptotic PKC signalingMaternal diabetes-induced oxidative stress activates PKC α, βII, δ, while it inhibits PKCε, ξ. Activated PKCα induces lipid peroxidation, which in turn aggravates oxidative stress, and induces apopto...

Peixin Yang, E. Albert Reece, Fang Wang, Rinat Gabbay-Benziv

Decoding the oxidative stress hypothesis in diabetic embryopathy through proapoptotic kinase signaling

American Journal of Obstetrics and Gynecology, Volume 212, Issue 5, 2015, 569–579

http://dx.doi.org/10.1016/j.ajog.2014.11.036

Figure 2. Oxidative stress-induced proapoptotic PKC signalingMaternal diabetes-induced oxidative stress activates PKC α, βII, δ, while it inhibits PKCε, ξ. Activated PKCα induces lipid peroxidation, which in turn aggravates oxidative stress, and induces apopto...

Peixin Yang, E. Albert Reece, Fang Wang, Rinat Gabbay-Benziv

Decoding the oxidative stress hypothesis in diabetic embryopathy through proapoptotic kinase signaling

American Journal of Obstetrics and Gynecology, Volume 212, Issue 5, 2015, 569 –579

http://dx.doi.org/10.1016/j.ajog.2014.11.036

Figure 2. Oxidative stress-induced proapoptotic PKC signalingMaternal diabetes-induced oxidative stress activates PKC α, βII, δ, while it inhibits PKCε, ξ. Activated PKCα induces lipid peroxidation, which in turn aggravates oxidative stress, and induces apopto...

Peixin Yang, E. Albert Reece, Fang Wang, Rinat Gabbay-Benziv

Decoding the oxidative stress hypothesis in diabetic embryopathy through proapoptotic kinase signaling

American Journal of Obstetrics and Gynecology, Volume 212, Issue 5, 2015, 569–579

http://dx.doi.org/10.1016/j.ajog.2014.11.036

Figure 2. Oxidative stress-induced proapoptotic PKC signalingMaternal diabetes-induced oxidative stress activates PKC α, βII, δ, while it inhibits PKCε, ξ. Activated PKCα induces lipid peroxidation, which in turn aggravates oxidative stress, and induces apopto...

Peixin Yang, E. Albert Reece, Fang Wang, Rinat Gabbay-Benziv

Decoding the oxidative stress hypothesis in diabetic embryopathy through proapoptotic kinase signaling

American Journal of Obstetrics and Gynecology, Volume 212, Issue 5, 2015, 569–579

http://dx.doi.org/10.1016/j.ajog.2014.11.036

Figure 2. Oxidative stress-induced proapoptotic PKC signalingMaternal diabetes-induced oxidative stress activates PKC α, βII, δ, while it inhibits PKCε, ξ. Activated PKCα induces lipid peroxidation, which in turn aggravates oxidative stress, and induces apopto...

Peixin Yang, E. Albert Reece, Fang Wang, Rinat Gabbay-Benziv

Decoding the oxidative stress hypothesis in diabetic embryopathy through proapoptotic kinase signaling

American Journal of Obstetrics and Gynecology, Volume 212, Issue 5, 2015, 569–579

http://dx.doi.org/10.1016/j.ajog.2014.11.036

Page 13: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Risk of major congenital anomalies

• 3% of all births- leading cause of infant mortality

• 5.7% of offspring of women with type 1 DM (Norwegian study)

• 6.6% of offspring of women with type 2DM (British study)

Page 14: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Relative risk (RR) for major congenital abnormalities from 14 studies of women with diabetes mellitus who did or did not receive preconception care (PCC).

Ray J et al. QJM 2001;94:435-444

© Association of Physicians

Page 15: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Does preconception care matter?

• PGDM w/o PCC– 41.4 % pre-term– 7.3% with birth defects– 4.4% perinatal death

• PGDM w/ universal PCC– 8400 pre-term births avoided– 3725 birth defects prevented– 1900 perinatal deaths avoided

Page 16: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Preventable health and cost burden of adverse birth outcomes associate with PGDM in the US

Peterson C, et al. Am J Obstet Gynecol 2015;212:74e1-9.

• PCC for known PGDM– $770 M in direct medical costs– $3.6B in lost productivity

• PCC for undiagnosed PGDM– $207M in direct medical costs– $960M in lost productivity

SO: approximately $5.5 billion in preventable costs!

Page 17: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Management goals

• Pregnancy outcomes no different from the general population– There is no more motivated patient with Diabetes than a

pregnant patient with Diabetes!– Nearly all of the work in this area focused on Type 1

patients but the future is in women with pre-existing Type II Diabetes

Page 18: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Management goals

• No unplanned pregnancies (but <50% are planned)– Start discussions with teenage girls early and often– Contraception-

• OCA’s acceptable but must monitor for BP changes• IUD• Barrier methods• Abstinence?• Plan B

Page 19: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Management goals

• Pre-conception assessment- Pre-existing Diabetes– Complication status and stability– Glycemic control– Nutritional management awareness- CHO

counting skills– Emotional readiness for pregnancy– Start folic acid early

Page 20: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Management goals (Pre-gestational pre-diabetes)

• Pre-conception evaluation of at risk women– Previous GDM– Pre-Diabetes (A1C≥5.7%), HTN, ASCVD– Family history– PCOS or other insulin resistance states– Acanthosis nigricans– Overweight (BMI>25!)

Page 21: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

ADA Guidelines- 2016

• New recommendation– Counsel all women of child-bearing age about the

importance of “near-normal” glycemia prior to conception

– Major malformations directly proportional to HgbA1C levels in the first 10 weeks of pregnancy

– Discuss family planning and effective contraception until the woman is prepared and ready

Page 22: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Pre-pregnancy evaluation:2016 ADA Recommendations

• HgbA1C• Serum creatinine• Urine

albumin/creatinine• TSH• Comprehensive eye

evaluation

• Medication review for possible teratogens inc. ACE-i and statins

Page 23: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Management goals

• Consider modifying medical regimen if pregnancy is anticipated or if unintended pregnancy likely– Intensify insulin regimen/pump therapy– Statins, TZD’s, ACE’s and ARB’s are contraindicated in

pregnancy!– Metformin and glyburide may be continued if achieving

adequate glycemic control

Page 24: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

The National Agenda for Public Health Action(ADA, APHA, CDC and P…)

• 10 priority recommendations including:– Encourage and support state programs to develop

prevention programs– Expand community based health promotion– Strengthen advocacy– Expand population based surveillance– Educate community leaders about Diabetes– Encourage healthcare providers to promote risk

assessment…– Encourage access to trained professionals– Conduct public health research

Page 25: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Impediments to PCC

• General health status-women with chronic illness are more likely to have unplanned pregnancy

• Socioeconomic status including health insurance• Co-existent tobacco and/or alcohol use• Contraceptive use- ½ of women with unplanned

pregnancy were not using contraception. Low rates of use in Diabetic women

Page 26: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

Health Literacy and Pregnancy Preparedness

• Lower health literacy linked to:– Lack of high school diploma– Lower socioeconomic status– Unplanned pregnancy– Lower probability of pre-conception discussion with endocrinologist or

obstetrician– Lower probability of pre-conception folic acid ingestion– Greater probability of hospitalization during pregnancy

Endres LK et al. Diabetes Care: 27; 331-4.

Page 27: Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada

And then what?

• Encourage lifestyle modification to reduce risk of persistent dysglycemia and overweight– 30-50% of women with GDM will develop Type 2

DM• Encourage nursing

– Reduction of risk by up to 50% • Counsel on the importance of planning future

pregnancies and offer birth control